Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

1,224

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

July 22, 2023

Study Completion Date

December 1, 2024

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS

The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.

BIOLOGICAL

Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS

The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.

BIOLOGICAL

Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP

The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe

BIOLOGICAL

Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP

The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe

Trial Locations (1)

Unknown

Icddr,B Study Clinics, Dhaka

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

collaborator

World Health Organization

OTHER

collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Centers for Disease Control and Prevention

FED